SCHEMBL3345945

SCHEMBL3345945

Fc1ccc(-c2noc(-c3cn4cc(C(F)(F)F)cc(Br)c4n3)n2)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.48
RAB9A P51151 5/20 0.48
NFKB1 P19838 4/20 0.48
NFKB2 Q00653 4/20 0.48
RELA Q04206 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
LMNA P02545 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
RECQL P46063 1/20 0.48
CNR2 P34972 12/20 0.44
MAPT P10636 2/20 0.42
PKM P14618 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CNR1 P21554 7/20 0.38
S1PR1 P21453 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3343018 0.91 NPC1 (0.60) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL3340122 0.88 SMN1; SMN2 (0.56) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL3339960 0.88 NPC1 (0.48) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL3343764 0.87 NPC1 (0.39) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL3339985 0.87 NPC1 (0.39) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL3340594 0.85 NPC1 (0.46) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL3340987 0.84 NPC1 (0.39) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL3343416 0.84 SMN1; SMN2 (0.58) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL3340394 0.83 SMN1; SMN2 (0.55) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL3340726 0.82 NPC1 (0.60) NPC1RAB9ANFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
WO-2010065760-A1 IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION EXELIXIS, INC. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 NPC1 241/4885RAB9A 2844/4885NFKB1 3452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.